Randomized phase III study of rituximab with intensified CHOP [cyclophosphamide + doxorubicin + vincristine + prednisone] chemotherapy versus rituximab with high-dose sequential therapy and autologous stem cell transplantation in adult patients (18-65 years) with stage II-IV high-intermediate or high risk DLBCL [diffuse large B-cell lymphoma]

Trial Profile

Randomized phase III study of rituximab with intensified CHOP [cyclophosphamide + doxorubicin + vincristine + prednisone] chemotherapy versus rituximab with high-dose sequential therapy and autologous stem cell transplantation in adult patients (18-65 years) with stage II-IV high-intermediate or high risk DLBCL [diffuse large B-cell lymphoma]

Completed
Phase of Trial: Phase III

Latest Information Update: 25 Sep 2014

At a glance

  • Drugs Rituximab (Primary) ; Antineoplastics
  • Indications Diffuse large B cell lymphoma
  • Focus Therapeutic Use
  • Acronyms HOVON 63 NHL
  • Most Recent Events

    • 01 Jan 2009 Status changed from active, no longer recruiting to completed, according to the current controlled trials (ISRCTN) record.
    • 08 Feb 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top